Efficacy and Safety of Adjuvant Pemetrexed Plus Cisplatin for Adenocarcinoma of Lung

Inclusion Criteria: * Adenocarcinoma of Lung * Postoperative pathologic stage IB\~IIIA * Complete surgical resection (R0 resection) N1-2: R0 resection with lobectomy and mediastinal lymph nodes dissection (MLND) N0: R0 resection with lobectomy with or without MLND * Adjuvant treatment should start between 4 to 6 weeks after surgery * ECOG performance status 0-1 * Weight loss during last 3 months should be less than 10%. * Normal hematologic, hepatic and renal function Neutrophil count \> 1500 /microliter, Platelet \> 100,000/microliter, Hemoglobin \> 9 g/dL Bilirubin \<=1.5 x upper limit normal, transaminase \< 2.5 x upper limit normal Serum Creatinine \<=1.5 mg/dL * Women in child bearing age should consent using contraceptive measures, and must have negative pregnancy test. Exclusion Criteria: * Other malignant neoplastic disease within 5 years. * Neoadjuvant chemotherapy before surgery of lung cancer * Patients who will be treated with postoperative radiation. * Stage IIIB or IV lung cancer * Severe infection, or cardiorespiratory, hematologic illness * HIV positive cases * Pregnancy or lactating women * Autoimmune diseases or those who receiving immune suppressive treatment * Symptomatic neuropathy \> CTCAE grade 1 * Those who consented other clinical trials within 3 months * Other significant medical conditions contraindicated to clinical trial